Ixabepilone
- Generic Name
- Ixabepilone
- Brand Names
- Ixempra
- Drug Type
- Small Molecule
- Chemical Formula
- C27H42N2O5S
- CAS Number
- 219989-84-1
- Unique Ingredient Identifier
- K27005NP0A
- Background
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue ...
- Indication
用于在其他化学治疗均失效后作为治疗晚期乳腺癌的药物。
- Associated Conditions
- Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer
- Associated Therapies
- -
Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral Cavity
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 144
- Registration Number
- NCT00033618
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
BMS-247550 in Treating Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT00006221
- Locations
- 🇺🇸
Cancer Therapy and Research Center, San Antonio, Texas, United States
🇺🇸Veterans Affairs Medical Center - San Antonio (Murphy), San Antonio, Texas, United States
🇺🇸University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00025194
- Locations
- 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
BMS-247550 in Treating Patients With Advanced Pancreatic Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00016965
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00052572
- Locations
- 🇺🇸
Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00016393
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Oregon Cancer Institute, Portland, Oregon, United States
Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00045097
- Locations
- 🇺🇸
Suburban Hospital, Bethesda, Maryland, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸Oncology Care Associates, Bethesda, Maryland, United States
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-15
- Target Recruit Count
- 30
- Registration Number
- NCT00030108
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
BMS-247550 in Treating Patients With Stage IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT00036764
- Locations
- 🇺🇸
New York University Clinical Cancer Center, New York, New York, United States
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Montefiore Medical Center
- Registration Number
- NCT00030706
- Locations
- 🇺🇸
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.